DUL Stock Overview
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Alnylam Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$227.20 |
| 52 Week High | US$227.20 |
| 52 Week Low | US$113.52 |
| Beta | 0.54 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 51.27% |
| 3 Year Change | n/a |
| 5 Year Change | 94.19% |
| Change since IPO | 1,162.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| DUL | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 1.8% |
| 1Y | 51.3% | -21.9% | 4.2% |
Return vs Industry: DUL exceeded the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: DUL exceeded the German Market which returned 4.7% over the past year.
Price Volatility
| DUL volatility | |
|---|---|
| DUL Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DUL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DUL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,665 | Yvonne Greenstreet | www.alnylam.com |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company’s pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1).
Alnylam Pharmaceuticals, Inc. Fundamentals Summary
| DUL fundamental statistics | |
|---|---|
| Market cap | €25.38b |
| Earnings (TTM) | -€1.14b |
| Revenue (TTM) | €924.98m |
27.4x
P/S Ratio-22.3x
P/E RatioIs DUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DUL income statement (TTM) | |
|---|---|
| Revenue | US$960.92m |
| Cost of Revenue | US$155.22m |
| Gross Profit | US$805.70m |
| Other Expenses | US$1.99b |
| Earnings | -US$1.18b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.61 |
| Gross Margin | 83.85% |
| Net Profit Margin | -123.02% |
| Debt/Equity Ratio | -1,502.1% |
How did DUL perform over the long term?
See historical performance and comparison